Continuous venous infusion of vindesine in metastatic breast cancer: Experience with a subcutaneously implanted system and portable pump

D. Amoroso, G. Bertelli, P. Pronzato, M. G. Vidili, M. Gulisano, R. Lionetto, R. Rosso

Research output: Contribution to journalArticle

Abstract

Fourteen patients with advanced pretreated breast cancer were treated with vindesine in continuous venous infusion (1.5 mg/sm/24 hours for 72 hours every 3 weeks). A totally implanted venous access and a portable pump were used. A total of 33 courses was administered. No objective response was observed and treatment was stopped. Drug-related toxicity consisted mainly of alopecia (64% of patients), nausea and vomiting (29%) and mucositis (29%). Catheter- related toxicity was observed in 6 patients (43%) and consisted of infection of the skin pocket in 4 patients and dislodging of the needle and catheter break in one patient. The feasibility of continuous venous infusion of vesicant drugs in outpatients is discussed.

Original languageEnglish
Pages (from-to)141-144
Number of pages4
JournalAnticancer Research
Volume9
Issue number1
Publication statusPublished - 1989

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this